example of oxyamination of azlactones with oxaziridines was realized using a chiral bisguanidinium salt. Efficient catalytic asymmetric oxyamination and kinetic resolution of oxaziridines occurred simultaneously. Various chiral oxazolin-4-one derivatives with potential biological activity were obtained (up to 92% ee). Meanwhile, a series of optically pure oxaziridines were recovered with up to 99% ee and
Catalytic, Enantioselective α‐Alkylation of Azlactones with Nonconjugated Alkenes by Directed Nucleopalladation
作者:Sri Krishna Nimmagadda、Mingyu Liu、Malkanthi K. Karunananda、De‐Wei Gao、Omar Apolinar、Jason S. Chen、Peng Liu、Keary M. Engle
DOI:10.1002/anie.201814272
日期:2019.3.18
palladium(II)‐catalyzed enantioselective α‐alkylation of azlactones with nonconjugated alkenes is described. The reaction employs a chiral BINOL‐derived phosphoric acid as the source of stereoinduction, and a cleavable bidentate directing group appended to the alkene to control the regioselectivity and stabilize the nucleopalladated alkylpalladium(II) intermediate in the catalytic cycle. A wide range of
An asymmetric inverse-electron-demandhetero-Diels-Alderreaction between o-quinone methides and azlactones to generate potentially pharmacological active dihydrocoumarins has been achieved efficiently by using a chiral N,N'-dioxide-Sc(III) complex as the catalyst. The desired products were obtained in high yields with excellent enantioselectivities and diastereoselectivities (up to 94% yield, 96%
[EN] NMDA RECEPTOR MODULATORS AND PRODRUGS, SALTS, AND USES THEREOF<br/>[FR] MODULATEURS DU RÉCEPTEUR NMDA ET PROMÉDICAMENTS, SELS ET UTILISATIONS DE CES DERNIERS
申请人:NAUREX INC
公开号:WO2015065891A1
公开(公告)日:2015-05-07
Disclosed are compounds having enhanced potency in the modulation of NMD A receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.